AB20 | 价格

AB20-1mg / 询价

Anti-TROP-2 Antibody (Sacituzumab Biosimilar)

产品信息(Product Info)
反应种属(Reactivities)

Human/Cynomolgus

靶点(Target)

TROP-2

同型(Isotype)

Human IgG1-Kappa

标记(Conjugation)

Unconjugated

纯化(Purification)

protein A

无菌(Sterility)

0.2 μM filtered

制剂(Formulation)

PBS, 10% glycerol (pH 7.4)

内毒素(Endotoxin)

Less than 1 EU per μg by the LAL method.

稀释缓冲液
(Recommended Dilution Buffer)

PBS (pH 7.4), contains no stabilizers or preservatives.

纯度(Purity)

<p style="line-height: 25px;">> 95% as determined by Bis-Tris PAGE<br />> 95% as determined by HPLC</p>

存储(Storage)

<p style="line-height: 25px;">Valid for 12 months from date of receipt when stored at -80°C.<br />Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.</p>

应用(Applications)

ELISA

产品数据(Assay Data)
Bis-Tris PAGE
Sacituzumab Biosimilar on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
SEC-HPLC
The purity of Sacituzumab Biosimilar is greater than 95% as determined by SEC-HPLC.
ELISA Data
Immobilized Human TROP-2, His Tag at 0.5μg/ml (100μl/well) on the plate. Dose response curve for Sacituzumab Biosimilar with the EC50 of 2.2ng/ml determined by ELISA. (QC Test)
背景(Background)

Trop-2, also known as epithelial glycoprotein-1 antigen (EGP-1), is a protein that in humans is encoded by the TACSTD2 gene. Mutations of this gene result in gelatinous drop-like corneal dystrophy, an autosomal recessive disorder characterized by severe corneal amyloidosis leading to blindness.

文献(References)

(1) Goldenberg D M , Cardillo T M , Govindan S V , et al. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*[J]. Oncotarget, 2015, 6(26).